Biogen (BIIB) Current Ratio: History & Chart

Biogen Inc.(BIIB)

Drug Manufacturers - General · Cambridge, MA

$211.32-1.19 (-0.56%)

Delayed quote: Sep 9, 2026, 10:35 AM EDT

About Biogen Inc.

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.

Cambridge, MA

7,500 employees

www.biogen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Christopher A. Viehbacher

View full financials

BIIB Current Ratio Metrics

CURRENT RATIO

1.87

CURRENT RATIO AVG TTM

2.57

CURRENT RATIO AVG 3Y

2.17

CURRENT RATIO AVG 5Y

2.22

CURRENT RATIO AVG 10Y

2.29

CURRENT RATIO AVG 15Y

2.32

CURRENT RATIO AVG 20Y

2.43

CURRENT VS TTM AVG

-27.30%

CURRENT VS 3Y AVG

-14.06%

CURRENT VS 5Y AVG

-15.86%

CURRENT VS 10Y AVG

-18.68%

CURRENT VS 15Y AVG

-19.46%

CURRENT VS 20Y AVG

-23.24%

SECTOR MEDIAN · HEALTHCARE

1.54

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

+21.11%

vs the sector median at left

NAME	MARKET CAP	CURRENT RATIO	TTM	3Y	5Y
Biogen Inc. (BIIB)	$31.22B	1.87	2.57	2.17	2.22
Zoetis Inc. (ZTS)vs ›	$30.75B	3.08	2.39	2.63	2.90
Centene Corp. (CNC)vs ›	$31.70B	1.15	1.40	1.24	1.19
ResMed Inc. (RMD)vs ›	$31.77B	3.10	3.27	3.06	2.80
Waters Corporation (WAT)vs ›	$30.60B	1.86	1.92	2.08	2.07
DexCom, Inc. (DXCM)vs ›	$31.97B	1.73	1.67	2.04	3.15
GE HealthCare Technologies Inc. (GEHC)vs ›	$30.01B	1.02	1.09	1.07	1.01
Medline Inc. (MDLN)vs ›	$29.41B	4.33	3.84	3.94	3.94
Alcon Inc. (ALC)vs ›	$33.52B	2.09	2.45	2.29	2.26
Alnylam Pharmaceuticals, Inc. (ALNY)vs ›	$33.94B	3.05	2.77	3.03	3.44

NAME

MARKET CAP

CURRENT RATIO

TTM

Biogen Inc. (BIIB)

$31.22B

1.87

2.57

2.17

2.22

Zoetis Inc. (ZTS)vs ›

$30.75B

3.08

2.39

2.63

2.90

Centene Corp. (CNC)vs ›

$31.70B

1.15

1.40

1.24

1.19

ResMed Inc. (RMD)vs ›

$31.77B

3.10

3.27

3.06

2.80

Waters Corporation (WAT)vs ›

$30.60B

1.86

1.92

2.08

2.07

DexCom, Inc. (DXCM)vs ›

$31.97B

1.73

1.67

2.04

3.15

GE HealthCare Technologies Inc. (GEHC)vs ›

$30.01B

1.02

1.09

1.07

1.01

Medline Inc. (MDLN)vs ›

$29.41B

4.33

3.84

3.94

Alcon Inc. (ALC)vs ›

$33.52B

2.09

2.45

2.29

2.26

Alnylam Pharmaceuticals, Inc. (ALNY)vs ›

$33.94B

3.05

2.77

3.03

3.44

Current Ratio FAQ

What is the current ratio for Biogen Inc. (BIIB)?

The current ratio for BIIB stock is 1.87.

Is Biogen Inc.'s current ratio high or low?

The current ratio of 1.87 is 16% below its 5-year average of 2.22, around the middle of its 5-year range (1.26–3.27).

What is the TTM average current ratio for Biogen Inc. (BIIB)?

The TTM average current ratio for BIIB stock is 2.57.

What is the 3Y average current ratio for Biogen Inc. (BIIB)?

The 3Y average current ratio for BIIB stock is 2.17.

What is the 5Y average current ratio for Biogen Inc. (BIIB)?

The 5Y average current ratio for BIIB stock is 2.22.

What is the 10Y average current ratio for Biogen Inc. (BIIB)?

The 10Y average current ratio for BIIB stock is 2.29.

What is the 15Y average current ratio for Biogen Inc. (BIIB)?

The 15Y average current ratio for BIIB stock is 2.32.

What is the 20Y average current ratio for Biogen Inc. (BIIB)?

The 20Y average current ratio for BIIB stock is 2.43.

DATE	CURRENT RATIO
2026-06-30	1.87
2026-03-31	3.06
2025-12-31	2.68
2025-09-30	2.72
2025-06-30	2.50
2025-03-31	1.44
2024-12-31	1.35
2024-09-30	1.26
2024-06-30	2.29
2024-03-31	2.10
2023-12-31	2.00
2023-09-30	1.68
2023-06-30	3.27
2023-03-31	3.24
2022-12-31	2.99
2022-09-30	2.49
2022-06-30	1.94
2022-03-31	2.01
2021-12-31	1.83
2021-09-30	1.70
2021-06-30	2.15
2021-03-31	2.12
2020-12-31	1.84
2020-09-30	2.06
2020-06-30	2.46
2020-03-31	1.73
2019-12-31	1.72
2019-09-30	1.91
2019-06-30	2.46
2019-03-31	2.84
2018-12-31	2.32
2018-09-30	2.75
2018-06-30	2.36
2018-03-31	3.23
2017-12-31	2.34
2017-09-30	2.19
2017-06-30	2.10
2017-03-31	2.29
2016-12-31	2.55
2016-09-30	3.24
2016-06-30	2.96
2016-03-31	2.59
2015-12-31	2.60
2015-09-30	3.52
2015-06-30	2.20
2015-03-31	2.70
2014-12-31	2.04
2014-09-30	2.25
2014-06-30	2.05
2014-03-31	2.21
2013-12-31	1.81
2013-09-30	1.74
2013-06-30	1.93
2013-03-31	4.16
2012-12-31	1.96
2012-09-30	2.01
2012-06-30	2.00
2012-03-31	2.00
2011-12-31	3.26
2011-09-30	3.20
2011-06-30	2.82
2011-03-31	2.69
2010-12-31	2.42
2010-09-30	2.58
2010-06-30	2.98
2010-03-31	3.53
2009-12-31	3.47
2009-09-30	3.57
2009-06-30	3.41
2009-03-31	3.07
2008-12-31	2.66
2008-09-30	2.68
2008-06-30	2.44
2008-03-31	3.03
2007-12-31	1.08
2007-09-30	0.81
2007-06-30	0.78
2007-03-31	3.88
2006-12-31	2.94
2006-09-30	2.80
2006-06-30	2.90
2006-03-31	3.06
2005-12-31	2.78
2005-09-30	2.75
2005-06-30	3.32
2005-03-31	1.61
2004-12-31	1.53
2004-09-30	2.95
2004-06-30	3.80
2004-03-31	4.32
2003-12-31	4.54
2003-09-30	4.57
2003-06-30	5.06
2003-03-31	4.36
2002-12-31	3.73
2002-09-30	4.19

DATE

CURRENT RATIO

2026-06-30

1.87

2026-03-31

3.06

2025-12-31

2.68

2025-09-30

2.72

2025-06-30

2.50

2025-03-31

1.44

2024-12-31

1.35

2024-09-30

1.26

2024-06-30

2.29

2024-03-31

2.10

2023-12-31

2.00

2023-09-30

1.68

2023-06-30

3.27

2023-03-31

3.24

2022-12-31

2.99

2022-09-30

2.49

2022-06-30

1.94

2022-03-31

2.01

2021-12-31

1.83

2021-09-30

1.70

2021-06-30

2.15

2021-03-31

2.12

2020-12-31

1.84

2020-09-30

2.06

2020-06-30

2.46

2020-03-31

1.73

2019-12-31

1.72

2019-09-30

1.91

2019-06-30

2.46

2019-03-31

2.84

2018-12-31

2.32

2018-09-30

2.75

2018-06-30

2.36

2018-03-31

3.23

2017-12-31

2.34

2017-09-30

2.19

2017-06-30

2.10

2017-03-31

2.29

2016-12-31

2.55

2016-09-30

3.24

2016-06-30

2.96

2016-03-31

2.59

2015-12-31

2.60

2015-09-30

3.52

2015-06-30

2.20

2015-03-31

2.70

2014-12-31

2.04

2014-09-30

2.25

2014-06-30

2.05

2014-03-31

2.21

2013-12-31

1.81

2013-09-30

1.74

2013-06-30

1.93

2013-03-31

4.16

2012-12-31

1.96

2012-09-30

2.01

2012-06-30

2.00

2012-03-31

2.00

2011-12-31

3.26

2011-09-30

3.20

2011-06-30

2.82

2011-03-31

2.69

2010-12-31

2.42

2010-09-30

2.58

2010-06-30

2.98

2010-03-31

3.53

2009-12-31

3.47

2009-09-30

3.57

2009-06-30

3.41

2009-03-31

3.07

2008-12-31

2.66

2008-09-30

2.68

2008-06-30

2.44

2008-03-31

3.03

2007-12-31

1.08

2007-09-30

0.81

2007-06-30

0.78

2007-03-31

3.88

2006-12-31

2.94

2006-09-30

2.80

2006-06-30

2.90

2006-03-31

3.06

2005-12-31

2.78

2005-09-30

2.75

2005-06-30

3.32

2005-03-31

1.61

2004-12-31

1.53

2004-09-30

2.95

2004-06-30

3.80

2004-03-31

4.32

2003-12-31

4.54

2003-09-30

4.57

2003-06-30

5.06

2003-03-31

4.36

2002-12-31

3.73

2002-09-30

4.19

Current Ratio: 1.87

BIIB Current Ratio

BIIB Average Current Ratio Chart

BIIB Current vs Average Current Ratio Chart

BIIB Current Ratio Metrics

BIIB Competitors' Current Ratio

Liquidity Analysis

Current Ratio Formula & Definition

Current Ratio FAQ

BIIB Current Ratio History

Related Metrics